CPT Code 83036: Hemoglobin; Glycosylated (A1c) Billing Guide

Key Takeaways

CPT code 83036 is defined as Hemoglobin; glycosylated (A1c), used to bill a laboratory measurement of glycated hemoglobin as a percentage of total hemoglobin.

Medicare covers CPT code 83036 under NCD 190.21; applicable ICD-10 codes include E10.x (Type 1 DM), E11.x (Type 2 DM), and R73.09 (prediabetes).

CPT 83036 applies to standard lab-based A1c testing; CPT 83037 is the distinct code for FDA-cleared home-use or point-of-care devices only.

Pabau’s claims management software helps practices pair CPT code 83036 with the correct ICD-10 diagnosis codes and track denial patterns before they compound.

Diabetes affects over 38 million Americans, and the hemoglobin A1c test is the cornerstone of managing every one of those patients. Yet CPT code 83036 generates a disproportionate share of claim denials, precisely because billers conflate it with 83037, apply the wrong ICD-10 pairings, or misread the QW modifier rules. A single documentation gap on a high-volume lab code like this compounds fast across a busy practice.

This guide covers every billing detail that matters for CPT code 83036: the official code descriptor, Medicare NCD 190.21 coverage parameters, the ICD-10 codes that establish medical necessity, how to apply modifiers correctly, documentation standards, and how to distinguish 83036 from 83037. Whether you bill for a primary care clinic, an endocrinology practice, or a metabolic health practice, the rules below apply directly to your workflow.

CPT Code 83036: Description and Clinical Purpose

According to the American Medical Association (AMA), CPT code 83036 is officially defined as “Hemoglobin; glycosylated (A1c).” It falls under the Chemistry Procedures subsection of the Pathology and Laboratory section of the CPT code set. The test measures the percentage of hemoglobin molecules in the blood that are coated with glucose, reflecting average blood glucose levels over the preceding two to three months.

Clinicians use this result for three distinct clinical purposes: diagnosing diabetes mellitus, monitoring long-term glycemic control in existing patients, and identifying individuals with prediabetes who require closer follow-up. Because the result reflects a 90-day window rather than a point-in-time glucose value, it provides a more stable picture of metabolic control than a fasting blood glucose alone.

• Code descriptor: Hemoglobin; glycosylated (A1c)
• Code section: Pathology and Laboratory, Chemistry Procedures
• What is measured: Percentage of glycated hemoglobin in whole blood
• Clinical window: Reflects average glucose over 60-90 days
• Common synonyms: HbA1c, glycated hemoglobin, glycosylated hemoglobin
• Related code: CPT 82985 (Glycated protein / fructosamine) also listed under Medicare NCD 190.21

The test is ordered through a reference lab such as Quest Diagnostics or Labcorp for standard send-out testing, or performed in-office using a point-of-care analyzer. Which setting applies determines whether you bill 83036 or its counterpart 83037. That distinction is covered in detail below.

CPT Code 83036 vs 83037: Choosing the Right Code

Misidentifying which A1c code applies is the most common source of claim errors for this test. The difference is not about who performs the test or what result it produces. The difference is about the device used.

CPT code 83036 does not specify a test location in its descriptor. As the CMS decision memo for NCD 190.21 explicitly notes, 83036 “does not preclude point of service testing.” What determines the correct code is whether the analyzer used holds FDA 510(k) clearance as a home-use device. If it does, bill 83037. If it is a standard laboratory analyzer without that specific clearance category, bill CPT code 83036 regardless of where in the clinic the test occurs.

Practices running in-office A1c testing through lab management workflows should document the analyzer model and its CLIA certification status in the patient record to support whichever code is billed.

Medicare Coverage for CPT Code 83036: NCD 190.21

Medicare covers CPT code 83036 under National Coverage Determination 190.21, titled Glycated Hemoglobin/Glycated Protein. NCD 190.21 is the governing federal policy for this code. CMS requires that a covered claim demonstrate medical necessity by linking 83036 to an appropriate diagnosis code from its approved list.

The NCD applies to Medicare Part B for outpatient laboratory services. When the test is ordered by a physician and performed by a reference laboratory billing directly to Medicare, the lab submits the claim. When an in-office in-house analyzer is used in a physician office laboratory, the practice submits the claim. The coverage logic under NCD 190.21 is the same in both scenarios.

CPT Code 83036 ICD-10 Codes That Establish Medical Necessity

The ICD-10-CM diagnosis codes listed below are commonly accepted under NCD 190.21 and commercial payer policies including Molina Healthcare (Policy G2006), Blue Cross Blue Shield of Texas, and Blue Cross Blue Shield of Oklahoma. Verify current LCD-level acceptance with your specific Medicare Administrative Contractor before submitting.

• E10.x – Type 1 diabetes mellitus (all fourth and fifth character extensions)
• E11.x – Type 2 diabetes mellitus (all fourth and fifth character extensions)
• E13.x – Other specified diabetes mellitus
• R73.09 – Other abnormal glucose (prediabetes)
• R73.01 – Impaired fasting glucose
• Z83.3 – Family history of diabetes mellitus (screening context)

A critical documentation requirement: the ICD-10 code submitted must reflect the specific manifestation of the patient’s diabetes where applicable. For example, E11.65 (Type 2 DM with hyperglycemia) is a more specific and clinically appropriate code than E11 alone for an uncontrolled patient. Specificity reduces denial risk. Using tracking tools within your measurements and tracking software to flag patients with active diabetes diagnoses can streamline correct code selection at the point of ordering.

CPT Code 83036 Frequency Limits Under Medicare

NCD 190.21 does not establish a hard national frequency limit for CPT code 83036 the way some preventive screening codes do. Coverage frequency is instead governed by MAC-level Local Coverage Determinations and clinical necessity documentation. The American Diabetes Association (ADA) Standards of Medical Care in Diabetes, which inform most LCD policies, recommend:

• Testing every 3 months (quarterly) for patients whose treatment has changed or who are not meeting glycemic targets
• Testing every 6 months for patients with well-controlled, stable diabetes
• Testing at diagnosis for newly identified patients

Billing CPT code 83036 more than four times per year for an individual Medicare patient warrants robust documentation supporting each test’s medical necessity. MAC auditors reviewing high-frequency claims will look for evidence in the clinical note that glycemic control changed or that treatment was adjusted. The note must not simply repeat “diabetes monitoring” as the justification for each quarterly claim.

CPT Code 83036 QW Modifier: When It Applies and When It Doesn’t

The QW modifier designates a test performed on a CLIA-waived analyzer in a physician office laboratory or other CLIA-waived setting. This modifier is not universally required for CPT code 83036. Whether it applies depends entirely on your CLIA certification level and the device in use.

• CLIA certificate of waiver: If your practice holds a CLIA waiver and uses an FDA-cleared waived analyzer, append QW to the CPT code (83036 QW or 83037 QW depending on the device classification)
• CLIA certificate of compliance or accreditation: Do not append QW. Standard lab claim without the modifier
• Reference lab billing: QW does not apply when a reference laboratory performs the test and bills under its own CLIA number

Blue Cross Blue Shield of Wyoming issued specific billing guidance starting January 1, 2024, requiring providers to include proper categorization on CPT code 83036 claims, with CLIA status and device documentation explicitly referenced. Commercial payers increasingly audit CLIA modifier accuracy. Submitting QW when your practice holds a compliance certificate, or omitting it when you hold a waiver, can trigger payer recoupment requests.

Centralizing CLIA certificate documentation in your compliance management system makes it faster to verify modifier accuracy before claims are submitted rather than after they are denied.

Reduce A1c claim denials with smarter billing workflows

Pabau's claims management tools help practices pair CPT code 83036 with the correct ICD-10 codes, track modifier accuracy, and catch denial patterns before they compound across your patient panel.

Book a demo

Documentation Requirements for CPT Code 83036

A clean CPT code 83036 claim requires documentation at three levels: the order, the result, and the clinical rationale. Missing any one layer creates a vulnerability in a payer audit. The clinical note must establish medical necessity, not just confirm that the test was ordered and resulted.

CPT Code 83036 Order Documentation

The ordering documentation must include the treating provider’s name, the specific test ordered (A1c or glycated hemoglobin), and the clinical indication. Generic standing orders without individualized diagnosis linkage are a common audit target. Each order should reflect the patient’s current diagnosis status, particularly where the ICD-10 code includes complication or manifestation extensions.

CPT Code 83036 Clinical Note Requirements

The clinical note for the encounter where 83036 is ordered or reviewed must document:

• Active diagnosis supporting the test (Type 1 DM, Type 2 DM, prediabetes, other specified DM)
• The patient’s current glycemic management plan (medications, dietary goals, insulin regime)
• Why the test is clinically indicated at this visit (stable monitoring, treatment change, new diagnosis, elevated glucose reading prompting follow-up)
• Result review at the follow-up visit, with documented response to the A1c result

Using structured digital forms and clinical templates that include prompts for diabetes diagnosis specificity and treatment documentation reduces the chance that a provider omits one of these elements under time pressure. For practices managing high volumes of diabetic patients, consistent note structure is a billing efficiency tool as much as a compliance one.

CPT Code 83036 CLIA and Laboratory Records

For in-house testing, maintain records of your CLIA certificate, the analyzer model and lot numbers used, quality control logs, and staff proficiency testing results. MAC auditors reviewing CPT code 83036 in-house claims can request CLIA documentation as part of a medical review. Reference lab claims require the lab’s NPI and CLIA number on the claim form, with the ordering provider’s NPI in the appropriate field.

CPT Code 83036 Reimbursement and Fee Schedule

Medicare reimbursement for CPT code 83036 is set through the Clinical Laboratory Fee Schedule (CLFS) rather than the Physician Fee Schedule, because it is a laboratory code without work RVU components. The CMS Physician Fee Schedule lookup tool can confirm current year rates for non-lab codes; for 83036 specifically, use the CMS Laboratory Fee Schedule for accurate reimbursement figures.

Commercial payer rates for CPT code 83036 vary significantly by contract and region. Reference labs negotiating directly with commercial payers typically receive rates different from what a physician office laboratory receives under its own contract. Practices billing 83036 from in-house analyzers should verify their contracted rate specifically for this code rather than assuming parity with the lab’s negotiated rate.

• Medicare rate basis: Clinical Laboratory Fee Schedule (CLFS), updated annually
• Rate variation: In-house physician office lab rates may differ from reference lab contracted rates
• Important caveat: Exact dollar figures change each calendar year; always confirm the current rate from CMS before quoting reimbursement in your practice
• Global billing: When CPT code 83036 is billed with an Evaluation and Management service on the same day, no separate global or professional component modifier is required for this laboratory code

Tracking reimbursement trends for CPT code 83036 across your payer mix through your claims management platform helps surface contract underpayments before they accumulate into material revenue loss. A rate 15% below contracted amount on a high-volume lab code is a significant recovery opportunity.

Common Denial Reasons for CPT Code 83036 and How to Avoid Them

Most CPT code 83036 denials cluster around four root causes. Each one is preventable with the right pre-submission workflow.

CPT Code 83036 Denial: Missing or Mismatched ICD-10

Submitting CPT code 83036 without a covered ICD-10 code, or submitting a non-specific code where a more specific one is available (e.g., using E11 rather than E11.9 or a manifestation code), generates a medical necessity denial. Payer systems crosswalk the submitted diagnosis against their NCD/LCD-derived coverage tables automatically. A code outside that table triggers an automatic denial regardless of the patient’s actual clinical situation.

Resolve this by building ICD-10 crosswalk prompts into your clinical forms and ordering workflow. When a provider selects A1c testing, the system should surface the patient’s active diabetes diagnosis codes for confirmation before the order is placed.

CPT Code 83036 Denial: Frequency Exceeded Without Documentation

A claim for a fifth or subsequent A1c in a calendar year, without a clinical note clearly documenting the reason for the additional test, will be denied by most MACs and commercial payers. The note must specifically address why quarterly monitoring has increased or why testing beyond the standard schedule is clinically necessary at this point in the patient’s care.

CPT Code 83036 Denial: Incorrect Modifier Application

Appending QW to a CPT code 83036 claim from a practice that holds a CLIA certificate of compliance rather than a certificate of waiver generates a modifier conflict denial. Conversely, omitting QW when billing from a waived setting can result in denial or recoupment. Verify your current CLIA certificate type before each plan year billing cycle begins and update your billing templates accordingly.

CPT Code 83036 Denial: Duplicate Claim Conflicts

When a reference laboratory bills Medicare directly for CPT code 83036 and the ordering physician practice also submits a claim for the same test on the same date of service, a duplicate denial results. Clarify in your practice’s billing protocols which entity is responsible for submission when a reference lab is involved, and do not bill separately for the interpretation of a lab result that the reference lab already billed as a technical component.

Billing CPT Code 83036 Alongside Other Diabetes Codes

CPT code 83036 is frequently billed at the same encounter as other diabetes-related services. Understanding how to pair it correctly avoids bundling denials and maximizes clean claim rate. Most primary care, endocrinology, and functional medicine practices managing diabetic patients will encounter these combinations regularly.

• CPT 83036 + E&M service (99213-99215): Bill separately on the same date of service. The lab code is not bundled with the E&M visit under standard Medicare and commercial payer rules. Ensure the E&M documentation supports a separate and distinct service
• CPT 83036 + CPT 82947 (Glucose, quantitative): Both may be billed on the same date when clinically indicated. Document the clinical rationale for ordering both tests simultaneously
• CPT 83036 + CPT 82985 (Glycated protein): Both appear in NCD 190.21’s covered code list. Fructosamine (82985) is sometimes ordered when A1c results may be unreliable due to hemoglobin variants. Document the specific clinical indication for ordering both
• CPT 83036 + diabetes screening codes (CPT 82947-series): Noridian’s LCD for diabetes screening addresses distinct preventive screening codes. Do not substitute CPT code 83036 for a covered screening code without verifying payer acceptance for that specific indication

For practices managing complex diabetic patients across multiple service lines, consistent practice management workflows that flag co-ordered lab codes for a billing review step before submission help prevent preventable bundling errors. This is particularly relevant in metabolic and functional medicine workflows where multiple panels are often ordered together.

Expert Resources for CPT Code 83036 Billing

Expert Picks

Need to verify your ICD-10 to CPT crosswalk for diabetes codes? Pabau Claims Management Software helps practices build structured ICD-10 pairings into ordering workflows to reduce medical necessity denials at the source.

Managing a metabolic health or diabetes-focused practice? Pabau Metabolic Health EMR covers lab ordering, results tracking, and billing workflow integration for practices running high volumes of A1c and glucose monitoring services.

Looking for the official CPT code descriptor and AMA guidance? AMA CPT Code Set Overview provides authoritative access to the CPT code set maintained by the American Medical Association, including official descriptors and update notices.

Need to confirm current Medicare fee schedule rates for CPT code 83036? CMS Physician Fee Schedule Lookup provides current year RVU data and reimbursement rates directly from CMS, updated annually.

Conclusion

CPT code 83036 is a high-volume, low-complexity code that generates disproportionate denial revenue when billed without the right ICD-10 pairing, modifier accuracy, or frequency documentation. The core vulnerabilities are consistent and predictable: mismatched diagnosis codes, QW modifier errors, and frequency claims that lack supporting clinical notes.

Pabau’s claims management software gives practices a structured workflow for pairing CPT code 83036 with the correct ICD-10 codes at the point of order, tracking modifier accuracy, and identifying denial patterns before they compound. To see how Pabau handles A1c billing workflows in practice, book a demo with the team.

Reviewed against current CMS NCD 190.21 coverage guidance, AMA CPT code set descriptors, and MAC LCD policies from Palmetto GBA and Noridian Healthcare Solutions.

Frequently Asked Questions